Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Author(s): Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

Keywords: Glycogen synthase kinase 3, molecular design, cancer treatment, kinase inhibitors, Wnt pathway

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [665 - 679]
Pages: 15
DOI: 10.2174/1381612811306040665
Price: $65

Article Metrics

PDF: 21